Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?

Is Inovio Pharmaceuticals a Good Coronavirus Stock to Buy?

The small biotech has some big hurdles to jump over the next few months.

The 3 Biggest Near-Term Risks That Inovio Faces

Inovio’s Q2 earnings and lingering questions about its INO-4800 vaccine are combining for a big drop for INOP stock.
The post Inovio Pharmaceuticals Shares Drop, Get a Downgrade appeared first on InvestorPlace.

Inovio Pharmaceuticals Shares Drop, Get a Downgrade

After a rough week on the stock market for the biotech company, investors finally think the price is right.

Why Inovio Pharmaceuticals Stock Is Up Today

Could this biotech stock be a major winner down the road?

Is Inovio Pharmaceuticals Stock a Buy?

Its experimental coronavirus vaccine has some of the best clinical data among the 167 candidates in development.

What's the Outlook for Inovio Pharmaceuticals Stock?

Questions about its coronavirus vaccine candidate continue to weigh on the biotech stock.

Why Inovio Stock Is Sinking Again Today

Inovio did not get the government funding or pre-orders like its competitors did, so if it happens later, INO stock will respond positively
The post Inovio Still Has a Chance to Break Out in a Big Way appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

Inovio Still Has a Chance to Break Out in a Big Way

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine.

Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer

Novavax

What looked like another rotation day turned into something more negative.

Stock Markets Take Late-Day Hit; Inovio, Novavax Plunge on Coronavirus Vaccine Concerns

Dynavax Technologies

Heat Biologics

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today

Stifel analysts cut their stock price target for Inovio Pharmaceuticals Inc. INO, -6.08% to $16 from $24 on Tuesday, after the company posted a wider-than-expected second-quarter loss and revenue that fell short of estimates.

Stifel cuts COVID-19 vaccine developer Inovio's price target as earnings and call leave more questions than answers

Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.

Inovio Coronavirus Vaccine To Enter Mid-To-Late Stage Testing In September

Inovio Pharmaceuticals, Inc. (INO) CEO J.

Inovio Pharmaceuticals Inc. INO, -6.08% shares fluctuated between slight gains and losses in the extended session Monday after the biotech company reported results that fell short of Wall Street estimates while it updated progress on its COVID-19 vaccine.

Inovio Pharma stock fluctuates after results, vaccine update

AstraZeneca

BioNTech SE

Merck

Moderna

Pfizer

COVID-19 has weakened the US economy more than China's.

T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

PLYMOUTH MEETING, Pa., Aug. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended.

INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update

Lack of detail in a clinical trial report weighed on the shares.

Why Inovio Fell 27.9% in July

Due to the government's desire to develop multiple vaccine candidates and several intriguing catalysts, INO stock deserves serious consideration.
The post It’s Time to Get Serious About Inovio Pharmaceuticals appeared first on InvestorPlace.

It’s Time to Get Serious About Inovio Pharmaceuticals

There are several reasons why the U.S. government might be choosing not to back the development of INO-4800 with big money, but two stand out.

Why Hasn't Inovio Won a Huge Coronavirus Vaccine Deal from Washington Yet?

Inovio stock will live and die by its coronavirus vaccine results. However, INO stock continues to trade well, with a solid chart setup.

What the Charts Say for Inovio Stock Right Now

So, what's the verdict? Stay on the sidelines with INO stock for now, but consider shares if they continue falling back to lower prices.

Hold Off Buying The Dip in Pandemic Play Inovio Stock

Inclusion in a government program to fight the spread of the coronavirus is a major catalyst event for INO stock.
The post It’s Warp Speed Ahead Now for Inovio appeared first on InvestorPlace.

It’s Warp Speed Ahead Now for Inovio

GlaxoSmithKline

Johnson & Johnson

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.

Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad

Inovio Pharmaceuticals: A Focus On The HPV Pipeline Candidates

News for Inovio Pharmaceuticals Stock (INO)